HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Gammaitoni, A. R. Articles by Schlagheck, T. Search for Related Content PubMed PubMed Citation Articles by Gammaitoni, A. R. Articles by Schlagheck, T.

Randomized, Double-Blind, Placebo-Controlled Comparison of the Analgesic Efficacy of Oxycodone 10 mg/Acetaminophen 325 mg versus Controlled-Release Oxycodone 20 mg in Postsurgical Pain

From Endo Pharmaceuticals, Inc., Chadds Ford, Pennsylvania (Dr. Gammaitoni, Dr. Galer, Dr. Caruso, Dr. Ma, Dr. Schlagheck); Jean Brown Associates, St. George, Utah (Dr. Bulloch); and Magidom Discovery, LLC, Westport, Connecticut (Dr. Lacouture).

This randomized, controlled trial compared the analgesic efficacy and safety of the new oxycodone 10-mg/acetaminophen 325-mg formulation (Percocet®) for the treatment of acute pain following oral surgery with double the dose of oxycodone alone (controlled-release [CR] oxycodone 20 mg [OxyContin®]). A total of 150 male and female patients with 2 full or partial bone-impacted mandibular molars, at least moderate persistent pain, and moderate trauma received a single dose of combination agent, CR oxycodone, or placebo following oral surgery and rated pain intensity and pain relief over the next 6 hours. The intent-to-treat population comprised 141 patients (55 on combination agent, 56 on oxycodone, and 30 on placebo). Combination agent and CR oxycodone were significantly superior to placebo for all efficacy measures. Combination agent was statistically superior to CR oxycodone in four of five outcome measures of pain intensity and pain relief (PPID, PPAR, SPID, and SPRID). It also provided a faster onset and 24% reduction in the number of patients reporting treatment-related adverse events compared with twice the dose of opioid alone. This new formulation offers the combination of two analgesic drugs with complementary mechanisms of action, which results in enhanced analgesia, an "opioid-sparing" effect, and an improved side effect and safety profile.

This article has been cited by other articles:

				A. Kogan, B. Medalion, E. Raanani, E. Sharoni, A. Stamler, N. Pak, B. A. Vidne, and L. A. Eidelman Early oral analgesia after fast-track cardiac anesthesia: [L'analgesie orale precoce apres la technique acceleree d'anesthesie cardiaque] Can J Anesth, April 1, 2007; 54(4): 254 - 261. [Abstract] [Full Text] [PDF]

				A. M. Levine and R. K. Burdick Controlled-Release Oxycodone J. Am. Acad. Ortho. Surg., January 1, 2005; 13(1): 1 - 4. [Full Text] [PDF]